文献速递肝病

肝硬化认知主诉患者中隐匿性肝性脑病以外的神经认知损害原因非常常见,可单独或与隐匿性肝性脑病并存

Other causes of neurocognitive impairment than covert hepatic encephalopathy (CHE) are very frequent, either alone or associated with CHE, in cirrhotic patients with cognitive complaints.
PubMed 文献 · Aliment Pharmacol Ther · 2024-07-07

前瞻性队列纳入123例因认知主诉转诊的肝硬化患者,采用完整神经心理学评估、脑电图及脑磁共振波谱检查,由裁决委员会诊断隐匿性肝性脑病。66%诊断为隐匿性肝性脑病,其中73%并存其他神经认知损害原因;无隐匿性肝性脑病者中48%心理测量肝性脑病评分异常、59%动物命名试验异常。特异性管理后复评77%临床改善;隐匿性肝性脑病而非其他原因与显性肝性脑病发生独立相关。

要点

  • 肝硬化认知主诉患者中66%诊断为隐匿性肝性脑病,其中73%并存其他神经认知损害原因。
  • 无隐匿性肝性脑病者中48%心理测量肝性脑病评分异常、59%动物命名试验异常。
  • 特异性管理后复评77%患者临床改善;隐匿性肝性脑病与显性肝性脑病发生独立相关。

核心结论

  • 肝硬化患者中隐匿性肝性脑病以外的神经认知损害原因常见,且常规隐匿性肝性脑病检测不能排除这些原因。
  • 神经认知损害原因影响预后;即使无隐匿性肝性脑病的患者管理后也获临床改善,作者强调对肝硬化认知主诉患者需多维度评估。

研究设计与样本

  • 前瞻性队列研究,纳入因认知主诉转诊至专病门诊的肝硬化患者123例(酒精/代谢功能障碍相关脂肪性肝病/病毒分别占63%/53%/14%,MELD=11)。
  • 检查包括完整神经心理学评估、脑电图及脑磁共振成像与波谱;隐匿性肝性脑病由包括医师/神经心理学家的裁决委员会诊断。

主要发现

  • 66%患者诊断为隐匿性肝性脑病,其中73%并存其他神经认知损害原因,主要为脑血管疾病/精神疾病。
  • 无隐匿性肝性脑病患者中48%心理测量肝性脑病评分异常、59%动物命名试验异常。
  • 特异性管理后复评的患者中77%临床改善。
  • 隐匿性肝性脑病而非其他神经认知损害原因与显性肝性脑病发生独立相关。

关键数值与推荐

  • 隐匿性肝性脑病诊断由包括医师/神经心理学家的裁决委员会作出。
  • 无隐匿性肝性脑病患者中48%心理测量肝性脑病评分异常、59%动物命名试验异常。

临床怎么用

  • 作者强调对肝硬化认知主诉患者需多维度评估;即使无隐匿性肝性脑病的患者管理后也获临床改善。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: Although it is well admitted that cirrhotic patients display various causes of neurocognitive impairment (NI) hampering the diagnosis of covert hepatic encephalopathy (CHE), those are almost never investigated per se. The aims of this study were, in cirrhotic patients displaying cognitive complaints explored by a complete multimodal work-up, to assess: (1) the prevalence of CHE and/or that of other causes of NI and (2) their outcomes, according to the cause of NI. METHODS: Prospective cohort of cirrhotic patients referred in a dedicated clinic because of cognitive complaints. Work-up included a complete neuropsychological assessment, electroencephalogram (EEG) and brain magnetic resonance imaging with spectroscopy. The diagnosis of CHE was made by an adjudication committee involving the physicians/neuropsychologist. RESULTS: One hundred and twenty-three patients were included (alcohol/MASLD/virus in 63/53/14%, MELD = 11). Sixty-six per cent of them were diagnosed with CHE; among them, 73% exhibited also other causes of NI, mainly cerebrovascular diseases/psychiatric. Among patients without CHE, 48% and 59% displayed pathological Psychometric Hepatic Encephalopathy Score and animal naming test, respectively. Clinical improvement was observed in 77% of the patients re-evaluated after specific management. CHE, but not the other causes of NI, was independently associated with OHE occurrence. CONCLUSION: Other causes of NI than CHE are frequent in patients with cirrhosis, and not ruled-out by the classical tests dedicated to CHE. Prognosis was influenced by the cause of NI. The management of patients even without CHE led to clinical improvement, underlining the need for a multifaceted approach of cirrhotic patients with cognitive complaints.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Sultanik P, Kheloufi L, Leproux A, et al. Other causes of neurocognitive impairment than covert hepatic encephalopathy (CHE) are very frequent, either alone or associated with CHE, in cirrhotic patients with cognitive complaints. Aliment Pharmacol Ther. 2024. PMID: 38973133. doi:10.1111/apt.18148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。